Editorial: Challenges and opportunities of TKIs in the treatment of NSCLC patients with uncommon mutations

Front Oncol. 2022 Jul 26:12:970315. doi: 10.3389/fonc.2022.970315. eCollection 2022.

Authors

Chunxia Su¹, Shi-Yong Sun²

Affiliations

¹ Department of Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
² Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, United States.

No abstract available

Keywords: immunotherapy; non-small cell lung cancer; resistance; targeted therapy; tyrosine kinase inhibitor; uncommon mutation.

Publication types

Editorial